3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Temozolomide
107
Radiotherapy
60
Radiation
28
Bevacizumab
19
Magnetic Resonance Spectroscopy
16
Nivolumab
15
Surgical Procedures, Operative
12
Irinotecan
11
Cyclophosphamide
10
Specimen Handling
9
Chemotherapy, Adjuvant
9
Radiotherapy, Intensity-Modulated
8
Radiosurgery
8
O(6)-benzylguanine
8
Carmustine
8
poly ICLC
7
pembrolizumab
7
motexafin gadolinium
7
fludarabine
7
Leukapheresis
7
Flucytosine
7
sargramostim
6
Radiotherapy, Conformal
6
Erlotinib Hydrochloride
6
Lomustine
5
Ipilimumab
5
Imiquimod
5
Imatinib Mesylate
5
Hydroxyurea
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioblastoma
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled